FibroGen to Report Fourth Quarter and Full Year 2021 Financial Results

Rhea-AI Summary

FibroGen, Inc. (NASDAQ: FGEN) will announce its fourth quarter and full year 2021 financial results on February 28, 2022, after market close. A conference call with investors is scheduled for the same day at 5:00 p.m. ET. This call will provide insights into the company’s corporate and financial performance.

Investors can access the call via the FibroGen website, with a replay available for 7 days post-call. FibroGen focuses on developing therapeutics for unmet medical needs, including treatments for anemia in chronic kidney disease and other conditions.

Positive

• Focus on innovative therapeutics targeting unmet medical needs.
• Products like roxadustat and pamrevlumab in clinical development.

Negative

• None.

SAN FRANCISCO, Feb. 14, 2022 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) will announce its fourth quarter and full year 2021 financial results on Monday, February 28 after the market close. FibroGen will also conduct a conference call on that day at 5:00 p.m. ET (2:00 p.m. PT) with the investment community to further detail the company's corporate and financial performance.

Conference Call and Audio Webcast
Interested parties may access a live audio webcast of the conference call via the FibroGen website at https://fibrogen.gcs-web.com/events-and-presentations/events. It is recommended that listeners access the website 15 minutes prior to the start of the call to download and install any necessary audio software.

Dial-In Information
Live (U.S./Canada): (877) 658-9081
Live (International): (602) 563-8732
Confirmation number: 1795663

A replay of the webcast and investor presentation will be available shortly after the call for a period of 7 days. To access the replay, please dial (855) 859-2056 (domestic) or (404) 537-3406 (international) and use passcode 1795663.

About FibroGen
FibroGen, Inc. is a biopharmaceutical company committed to discovering, developing, and commercializing a pipeline of first-in-class therapeutics. The Company applies its pioneering expertise in hypoxia-inducible factor (HIF) and connective tissue growth factor (CTGF) biology to advance innovative medicines for the treatment of unmet needs. The Company is currently developing and commercializing roxadustat, an oral small molecule inhibitor of HIF prolyl hydroxylase activity for anemia associated with chronic kidney disease (CKD), anemia associated with myelodysplastic syndromes (MDS), and for chemotherapy-induced anemia (CIA). Pamrevlumab, an anti-CTGF human monoclonal antibody, is in clinical development for the treatment of idiopathic pulmonary fibrosis (IPF), locally advanced unresectable pancreatic cancer (LAPC), and Duchenne muscular dystrophy (DMD). FibroGen recently expanded its research and development portfolio to include product candidates in the immuno-oncology and autoimmune space. For more information, please visit www.fibrogen.com.

Contacts: FibroGen, Inc.

Investors:
Michael Tung, M.D.
Corporate Strategy / Investor Relations
1.415.978.1434
mtung@fibrogen.com

Media:
Meichiel Keenan
Public Affairs
mkeenan@fibrogen.com

FAQ

When will FibroGen announce its fourth quarter and full year 2021 financial results?

FibroGen will announce its financial results on February 28, 2022, after market close.

What time will the FibroGen conference call be held?

The conference call will be held at 5:00 p.m. ET on February 28, 2022.

How can I access the FibroGen conference call?

You can access the conference call via the FibroGen website's audio webcast.

What is FibroGen's primary focus in its drug development?

FibroGen focuses on developing therapeutics for conditions like anemia in chronic kidney disease and other serious diseases.